



## Novel Research on the Diagnosis and Treatment of Melanoma

Guest Editors:

**Dr. Roberta Giuffrida**

**Dr. Stefania Guida**

**Dr. Caterina Dianzani**

**Dr. Claudio Conforti**

Deadline for manuscript  
submissions:

**closed (5 November 2025)**

### Message from the Guest Editors

Dear Colleagues,

Melanoma is the deadliest form of skin cancer, and it is thus critical to diagnose and treat it at the earliest stage of its development. In recent decades, enormous progress has been achieved in the diagnosis and treatment of melanoma.

Recent advancements in noninvasive diagnostic strategies have helped to increase sensitivity for the early detection of melanoma and reduce unnecessary surgical procedures, especially in patients with ambiguous melanocytic lesions.

Surgery remains the standard therapy in patients with a localized disease but is not curative for advanced melanoma. In the last ten years, developments in checkpoint inhibition and targeted therapy against melanoma have revolutionized the management of patients with advanced disease.

The aim of this Special Issue is to publish original research articles, reviews, hypotheses, communications and editorial letters to provide new insights into the diagnosis and treatment of melanoma.

Dr. Roberta Giuffrida  
Dr. Stefania Guida  
Dr. Caterina Dianzani  
Dr. Claudio Conforti  
*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)